Stella Pharma announced that it had entered into an agreement with Fujita Academy and Sumitomo Heavy Industries to conduct an exploratory study aimed at expanding BNCT into the deep-seated cancer field. The conclusion of the agreement was announced at 11:00 on 1 October, and specific initiatives toward implementation are under way.
Stella Pharma announced that it had entered into an agreement with Fujita Academy, Sumitomo Heavy Industries and others concerning the conduct of an “exploratory study on 18F-FBPA uptake in deep-seated cancer”. The agreement is positioned as a specific initiative toward conducting the study.
The study is part of a project aimed at expanding BNCT into the deep-seated cancer field, with related details disclosed on 10 August. The conclusion of the agreement is described as a specific step toward advancing the study as a practical initiative.
The news was reported by Traders Web, which is identified as the distributing source, and the cooperation framework for expanding application into the deep-seated cancer field is expected to be strengthened. The article does not discuss any direct impact on the market or share price movements.
The article mentions an individual named Saito Takumi (齋藤 匠), and progress on the project may attract attention as related news develops.